First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype

doi:10.3748/wjg.v21.i48.13548

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 48

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8625)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

632

WORD

417

HTML

4072

Tables (1-5)

189

Sum=5310

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1081

Download

2228

Sum=3309

Dec 28, 2015 (publication date) through Aug 1, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Dec 28, 2015; 21(48): 13548-13554
Published online Dec 28, 2015. doi: 10.3748/wjg.v21.i48.13548

Table 4 Correlation between pepsinogen I/II ratio and Helicobacter pylori eradication

Eradication	PG I/II ratio			Total
Eradication	Increase	No change	Decrease	Total
Success	26	26	1	53
Failure	4	18	3	25
Total	30	44	4	78

Serum PG I level and PG I/II ratio were significantly increased after eradication of Helicobacter pylori (P < 0.01). PG: Pepsinogen.

Citation: Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554
URL: https://www.wjgnet.com/1007-9327/full/v21/i48/13548.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i48.13548